Four of the top ten Phase III failures of 2010 that were listed at FierceBiotech on Oct 21st are cancer drugs, and that's a big number! read more...
ASA404 (vadimezan, formerly known as AS1404, DMXAA; Antisoma/Novartis) failed in a non-small cell lung cancer trial, ATTRACT-2. It is a small molecule Vascular Disrupting Agent (VDA) targeting established blood vessels in tumor. (read here and here)
NOV-002 (Novelos Therapeutics) also failed a non-small cell lung cancer trial. It is a proprietary formulation of oxidized glutathione, or “GSSG” in a 1000:1 ratio of GSSG with cisplatin.
Zibotentan (ZD4054, AstraZeneca) failed in prostate cancer. It is endothelin pathway blocker
Recentin (cediranib, AstraZeneca) for colon cancer also failed in a head-to-head study with Avastin. Recentin is a VEGFR tyrosine kinase inhibitor.
NV1FGF (Sanofi-Aventis and Vical), a proangiogenic agent, also did not deliver in TAMARIS trial. It did not prove superior to placebo in preventing death and disease from critical limb ischemia. It is a pCOR plasmid-based angiogenic gene therapy delivering FGF1 (read more).
Four of the five drugs listed above were targeting angiogenic signaling. Cancer remains a tough nut to crack but angiogenic pathways remain the bull's eye. As is often the case, these drugs may reappear in another trial in 2011.